Guidance maintained while retail comp guide dropped from flat to declining, propped up by a one-time tax rate cut and the final year of sale and leaseback gains.
Thesis: Adjusted EPS down 44% CC and FCF down $671M, but guidance holds only because tax planning moved the rate 400bps lower and sale and leaseback gains still contribute for one more year. The operating guide was cut: retail comp from flat to low-single-digit decline, prescription market growth down 50bps. Meanwhile Wentworth, 25 years in PBM, states on record that 'there is very little left in the tank' for reimbursement compression. WBA has zero leverage over the entity that sets its gross profit.
Verdict: SHORT — Conviction: HIGH
Catalyst: 2025 PBM contract negotiations and whether cost-plus or pay-for-performance models actually convert from pilot to material revenue. Management says 95% of 2024 done with 'good indications for 25' but provides no quantified contract value.
Key Risk: 2025 PBM contracts land better than expected, cost-plus models scale faster than a year or two, and VillageMD reaches breakeven with real full-risk lives leverage. Boots UK and Shields continue compounding.
The Tell: When asked if reimbursement has hit a floor, Wentworth says 'in my 25 years at PBM, the floor just kept moving lower' and 'there is very little left in the tank.' He then pivots to 'we've had a very successful 2024 negotiations...95% along the way...good indications for 25.' The admission of no pricing floor followed by vague reassurance on 25 is the tell.
Friction Level: HIGH_FRICTION — Bull sees a reimbursement model shift creating structural pricing power and a healthcare platform inflection. Bear sees a retailer with zero leverage over PBMs, guided up by non-recurring tax and SLL levers while core operating guidance was cut. Fundamental disagreement on whether the cost-plus shift is real or aspirational.
Report not found
The report data is no longer available. Please return to the archive.